CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Viridian posts first Lumvoa revenue but net loss widens

By Reuters News


Overview

  • U.S. biotech firm reported first net product revenue from Lumvoa after TED launch in Q3

  • Q3 net loss widened to $101.2 mln from $34.6 mln a year earlier

  • R&D expenses fell, while SG&A costs rose to support Lumvoa commercial activities


Outlook

  • Company plans BLA submission for elegrobart in TED in Q1 2027

  • VRDN-292 phase 1 trial in Graves’ disease expected to begin in Q4 2026

  • Company expects VRDN-008 phase 1 data and FcRn portfolio update in Q4 2026


Result Drivers

  • LUMVOA LAUNCH - Co reported $24.7 mln in net product revenue from Lumvoa in its first quarter of launch, with over 100 patients on therapy and progress in market access

  • HIGHER SG&A COSTS - SG&A expenses rose due to increased personnel and professional services to support Lumvoa commercial activities and organizational growth

  • LOWER R&D EXPENSES - R&D expenses declined, mainly due to reduced costs for veligrotug and elegrobart clinical studies, partly offset by higher investment in TSHR and FcRn programs and increased headcount


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$101.21 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Viridian Therapeutics, Inc. is $35.00, about 39.2% above its November 3 closing price of $25.15


Reuters Recommended Reads

  • Nov 3 - Beam Therapeutics posts wider than expected Q3 net loss as revenue drops

  • Nov 3 - Arvinas Q3 revenue drops sharply on lower milestone payments

  • Nov 2 - Immunovia Q3 net sales surge on PancreaSure uptake


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.